10-KPeriod: FY2008

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2008

Filed February 20, 2009For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) reported significant strategic divestitures and acquisitions in 2008, including the sale of its ConvaTec business for $4.1 billion, which contributed a substantial $2.0 billion gain after tax. The company also acquired Kosan Biosciences for oncology product development. These moves indicate a strategic shift towards a more focused biopharmaceutical business. Productivity Transformation Initiatives (PTI) were underway, aiming for $2.5 billion in annual savings by 2012 through operational efficiencies and cost reductions. Financially, net sales from continuing operations grew by 13% year-over-year, driven by strong performance in key products like PLAVIX and ABILIFY. Despite facing ongoing challenges from generic competition, particularly with the expiration of data protection for PLAVIX in the EU, BMY demonstrated resilience and growth through strategic alliances and product pipeline development.

Financial Highlights

56 data points
Beta

Revenue

$17.71B

70.0% Gross Margin

Net Income

$5.25B

29.6% Net Margin

EPS (Diluted)

$2.62

Total Assets

$29.49B

Cash & Equivalents

$7.98B

Free Cash Flow

$2.77B

Financial Statements
Beta
Revenue$17.71B
Cost of Revenue$5.32B
Gross Profit$12.40B
R&D Expenses$3.51B
SG&A Expenses$4.14B
Operating Expenses$12.94B
Operating Income$2.70B
Interest Expense$310.00M
Net Income$5.25B
EPS (Basic)$2.64
EPS (Diluted)$2.62

Key Highlights

  • 1Divestiture of ConvaTec business for $4.1 billion, resulting in a $2.0 billion after-tax gain, bolstering the company's financial flexibility.
  • 2Acquisition of Kosan Biosciences to enhance its oncology pipeline.
  • 3Productivity Transformation Initiative (PTI) aims for $2.5 billion in annual cost savings by 2012, demonstrating a focus on operational efficiency.
  • 4Net sales from continuing operations increased by 13% to $20.6 billion, driven by strong performances in PLAVIX (+18%) and ABILIFY (+30%).
  • 5Significant R&D investment of $3.6 billion in 2008, underscoring commitment to innovation and future growth.
  • 6Sale of ImClone shares for approximately $1.0 billion, contributing to improved net cash position.
  • 7Net cash position improved significantly to $1.5 billion due to divestiture proceeds and operating cash flows, a substantial turnaround from net debt in the prior year.

Frequently Asked Questions

Bristol-Myers Squibb made significant strategic divestitures and acquisitions in 2008. Notably, they divested their ConvaTec business for $4.1 billion, which resulted in a substantial $2.0 billion after-tax gain. They also acquired Kosan Biosciences to strengthen their oncology pipeline and sold their ImClone shares for $1.0 billion.

Key products like PLAVIX and ABILIFY drove significant growth in 2008. PLAVIX sales increased by 18% to $5.6 billion, and ABILIFY sales grew by 30% to $2.2 billion. The company faces challenges with PLAVIX due to the expiration of data protection in the EU, but the strong U.S. sales performance and ongoing patent litigation efforts suggest continued focus on maximizing its value.

The Productivity Transformation Initiative (PTI) is designed to fundamentally change how Bristol-Myers Squibb operates its business. The goal is to achieve $2.5 billion in annual productivity cost savings and cost avoidance by 2012 through measures like simplifying operations, standardizing processes, rationalizing the manufacturing network, and improving overall cost efficiency.

The company's financial position significantly improved in 2008. Divestitures, particularly the sale of ConvaTec, and the sale of ImClone shares generated substantial cash proceeds. This, combined with strong operating cash flow, allowed BMY to move from a net debt position in 2007 to a net cash position of $1.5 billion by the end of 2008, while also funding dividends and capital expenditures.